Cyllene Therapeutics
Develops DNA medicines for severe neurogenic bladder conditions and other neurological diseases
€33MSeries C
Role not disclosedTA
T. Andera Partners SAS
Activity from announced rounds
Activity in this selectionchemistryvc-773b1a46
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $37.7M 1 disclosed · full round size, not this investor’s share